Literature DB >> 31242809

Tissue stem cells: the new actors in the aneuploidy field.

Rita Brás1,2, Claudio E Sunkel1,3, Luís Pedro Resende1,2.   

Abstract

The development of multicellular organisms and the maintenance of its tissues relies on mitosis. However, this process represents a major challenge for genomic stability as each time a cell division occurs there are multiple steps where errors can lead to an abnormal chromosomal content in daughter cells - aneuploidy. Aneuploidy was first postulated to act as a tumour promoting agent over one century ago. Since then, we have learned to appreciate the complexity involving the cellular responses to aneuploidy and to value the importance of models where aneuploidy is induced in vivo and in a cell-type specific manner. Recent data suggests that stem cells evolved a distinct response to aneuploidy, being able to survive and proliferate as aneuploid. Since stem cells are the main cells responsible for tissue renewal, it is of the utmost importance to place the spotlight on stem cells within the aneuploidy field. Here, we briefly review some of the biological mechanisms implicated in aneuploidy, the relationship between aneuploidy and tissue pathologies, and summarize the most recent findings in Drosophila on how tissue stem cells respond to aneuploidy. Once we understand how stem cell behavior is impacted by aneuploidy, we might be able to better describe the complicated link between aneuploidy and tumourigenesis.

Entities:  

Keywords:  Stem cells; aneuploidy; cancer; mitosis

Year:  2019        PMID: 31242809      PMCID: PMC6681780          DOI: 10.1080/15384101.2019.1635867

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  101 in total

1.  The Configurations and Sizes of the Chromosomes in the Trivalents of 25-Chromosome Daturas.

Authors:  J Belling; A F Blakeslee
Journal:  Proc Natl Acad Sci U S A       Date:  1924-03       Impact factor: 11.205

2.  Genetical and Cytological Proof of Non-disjunction of the Fourth Chromosome of Drosophila Melanogaster.

Authors:  C B Bridges
Journal:  Proc Natl Acad Sci U S A       Date:  1921-07       Impact factor: 11.205

3.  The fourth chromosome of Drosophila melanogaster: interspersed euchromatic and heterochromatic domains.

Authors:  F L Sun; M H Cuaycong; C A Craig; L L Wallrath; J Locke; S C Elgin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

4.  Population-based analyses of mortality in trisomy 13 and trisomy 18.

Authors:  Sonja A Rasmussen; Lee-Yang C Wong; Quanhe Yang; Kristin M May; J M Friedman
Journal:  Pediatrics       Date:  2003-04       Impact factor: 7.124

5.  Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint.

Authors:  Daniela A Brito; Conly L Rieder
Journal:  Curr Biol       Date:  2006-06-20       Impact factor: 10.834

6.  Risks of leukaemia and solid tumours in individuals with Down's syndrome.

Authors:  H Hasle; I H Clemmensen; M Mikkelsen
Journal:  Lancet       Date:  2000-01-15       Impact factor: 79.321

7.  Exploiting the compromised spindle assembly checkpoint function of tumor cells: dawn on the horizon?

Authors:  Marc Schmidt; René H Medema
Journal:  Cell Cycle       Date:  2006-01-16       Impact factor: 4.534

Review 8.  An introduction to stem cells.

Authors:  Malcolm R Alison; Richard Poulsom; Stuart Forbes; Nicholas A Wright
Journal:  J Pathol       Date:  2002-07       Impact factor: 7.996

9.  Merotelic kinetochore orientation versus chromosome mono-orientation in the origin of lagging chromosomes in human primary cells.

Authors:  Daniela Cimini; Daniela Fioravanti; E D Salmon; Francesca Degrassi
Journal:  J Cell Sci       Date:  2002-02-01       Impact factor: 5.285

10.  Early aging-associated phenotypes in Bub3/Rae1 haploinsufficient mice.

Authors:  Darren J Baker; Karthik B Jeganathan; Liviu Malureanu; Carmen Perez-Terzic; Andre Terzic; Jan M A van Deursen
Journal:  J Cell Biol       Date:  2006-02-13       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.